-
Peaceful Repeat Vote in Douglas Ward 3 Amid Heightened Security
-
‘They want silence’: how the film NAZA is shaking Israel
-
Belgian Ambassador Marks King’s Day in Athens Amidst Strong Bilateral Trade Ties
-
Dún Laoghaire-Rathdown €335m Budget Faces Mixed Reaction Over Housing and Cost of Living
-
Rediff.com IPO Risks: Gmail Dominance and New Business Ventures
-
BING X: 22,624.66 SNC have disappeared at BingX – how safe are tokens on BingX? Will BingX’s MiCAR licence be suspended?
-
Dubai Police Expand Luxury Patrol Fleet with 525-hp Defender
-
Iran Strikes US Sites in Kuwait Following US Airstrikes on Qeshm Island
-
ESGold Expands Montauban Gold-Silver Property to Approximately 26,787 Hectares Through Strategic Claim Staking
-
Investments & Wealth Institute Expands Advanced Education Offerings for 2027, Announces Next Experience Conference in Nashville
-
Wedgewood Weddings Acquires Swan Lake Overlook, Where Alpacas, Deer, and Mountain Views Join the Guest List
-
DSS Announces Completion of Impact Biomedical Business Combination with Zoar Limited
-
Newsmax Expands Over-the-Air Reach with HC2 Broadcasting Distribution Agreement for Newsmax2
-
Impala and Philanthropy Southwest Launch Southwest Hub, Mapping Philanthropy Across Eight States
-
HTB Activ(TM) Trial Demonstrates Significant Improvement in Cognitive Abilities
-
Nixxy Announces 1-for-20 Reverse Stock Split
-
IGC Pharma Completes Dosing in Phase 2 CALMA Trial of IGC-AD1 for Agitation in Alzheimer's Dementia
-
The IRS Watchdog Just Published Its FY 2027 Challenges List - Clear Start Tax Explains Why Agency Strain Rarely Slows Down Collection Notices
-
Who Does the Best Deep Plane Facelift in Oklahoma?
-
LHH ICEO Research Led by Harvard Business School Professor Maps Four Paths for Work Beyond the C-Suite
-
cbdMD Applauds Introduction of the Bipartisan Hemp Guardrails Act, Calling It a Win for Consumer Safety, American Jobs and Tax Revenue
-
Bell Rose Capital (OTCID:BELR) Makes Major Move Into Streaming Entertainment With Spark TV Partnership And New Billy Carson Series "The Missing Chapter"
-
Tocvan Defines Priority Gold Target Areas at Gran Pilar From Project-Wide Soil Sampling and Geologic Mapping; 225 Soils at or Above 100 ppb Gold
-
NuRAN Wireless Raises First Two Towers in Benin as 4G Rollout Beats Expectations in Cameroon and Ivory Coast
-
Rockhaven Announces Successful Completion of 2026 Klaza Bulk Sample Program
-
Silver Storm to Attend the 121 Mining Investment Conference in London, UK
-
American Resources Corporation Provides Strategic Business and Financial Reporting Update
-
Who Does the Best Deep Plane Facelift in Sarasota?
-
Jumia Reports Third Quarter 2026 Results
-
Ameriwest Advances Its Copper Focused Strategy Through Proposed Sale of Railroad Valley to Pure Energy Minerals
-
1933 Industries Completes LED Lighting Retrofit at Its 68,000 Sq. Ft. Cannabis Cultivation Facility in Las Vegas, Nevada - Ranks #3 in Cannabis Flower Sales
-
AbTherx Licenses Atlas(TM) Platform to Athenova Therapeutics for Next-Generation Targeted Alpha Radiopharmaceutical Discovery
-
DataMeds AI Subsidiary Helomics, Inc. Announces Cancer Target Discovery and Anticancer Peptides Drug Development Partnership With DiaGen AI, Inc.
-
What to Do When Two Households Become One
-
SmartBuyerAI Gives Car Buyers an Itemized Check of Dealer Offers as FTC Steps Up Price Transparency Enforcement
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - November 18
-
Fulcrum Metals PLC Announces Uranium Readings up to 0.42% U(3)O(8) at Charlot-Neely
-
Leggett Dynamics Wins 2026 Automotive News PACE Pilot Award For Smart Brushless Motor
-
Wyyerd Fiber Brings Arizona's Fastest Internet to the City of Phoenix
-
Digital Infrastructure World 2027 Announces First 85 Speakers as Registrants Represent 80GW of AI Buying Capacity
-
Bill Shelow, LIBRA Insurance Partners President and CEO, Receives NAILBA’s 2026 Douglas Mooers Award for Excellence
-
Oleria Extends Identity Governance to AI Agents, Tracing Every Agent Through the People and Credentials It Acts For
-
UCLA's Scooter Jackson named Week 11 Lott IMPACT Trophy Player of the Week
-
Paris Hilton Guides Loti as Chief Advocacy Officer to Put Digital Identity Protection in Everyone's Hands
-
Ondas and Aston Martin Aramco Formula One Team Launch Multi-Year Partnership Built for "Speed to Decision"
-
Who Does the Best Testosterone Replacement Therapy in Las Vegas?
-
CMP 2026-2027 Nonprofit Leadership Pulse Check
-
Nexteer's HMDD Wins Innovation Awards from PACE Pilot, CES and AutoTech Breakthrough
-
Coa Wealth Launches AI-Powered Software That Functions as a Private Investment Office for Individual Investors and Families
-
More Than Keyboards: Epomaker Brings Its Gaming World to G-STAR 2026
President Trump Signals Openness to Medical Cannabis-MMJ BioPharma Files Emergency Motion to DEA Administrator Terry Cole
MMJ BioPharma is taking its fight for FDA approved cannabis medicine directly to DEA Administrator Terry Cole, as President Trump signals openness to marijuana's medical benefits. After seven years of delays, MMJ is ready to launch clinical trials for Huntington's disease and Multiple Sclerosis- if the DEA finally issues its long overdue API Bulk manufacturing registration.
WASHINGTON, DC / ACCESS Newswire / August 11, 2025 / MMJ BioPharma Cultivation announced today it will file an emergency motion directly to newly confirmed DEA Administrator Terrance "Terry" Cole, seeking immediate action on the company's long delayed application to grow pharmaceutical grade cannabis for FDA approved clinical trials in Huntington's disease and Multiple Sclerosis.

The move comes just hours after President Donald Trump addressed the nation on marijuana rescheduling, acknowledging the complex nature of the debate and expressing openness to medical applications.
"Some drugs are okay, but we're trying to clean up crime. How does marijuana go hand in hand? We're only looking at that. That's early, but you know, somebody reported about marijuana reclassification, which is fine - we're looking at it. Some people like it. Some people hate it. Some people hate the whole concept of marijuana because if it does bad for the children, it does bad for people that are older than children.
But we're looking at reclassification, and we'll make a determination, I would say, over the next few weeks. And that determination, hopefully, will be the right one. It's a very complicated subject - the subject of marijuana.
I've heard great things having to do with medical, and I've heard bad things having to do with just about everything else. But medical - for pain and various things - I've heard some pretty good things. For other things, I've heard some pretty bad things."
MMJ BioPharma's application to become a DEA-registered bulk manufacturer has been stalled for over seven years due to inconsistent guidance, procedural irregularities, and unconstitutional Administrative Law Judge (ALJ) proceedings. With no ALJ currently in place, the company is urging Administrator Cole to exercise his authority and approve the registration without further delay.
Why MMJ's Model Fits the President's Priorities
MMJ's approach directly addresses the balance President Trump emphasized between public safety and legitimate medical need:
FDA-Orphan Drug Designations for both Huntington's disease and Multiple Sclerosis.
Two Investigational New Drug (IND) applications on file with the FDA.
Good Manufacturing Practice (GMP) compliance ensuring safety, purity, and consistency.
Full alignment with federal law-separate from the recreational cannabis industry.
"President Trump's remarks recognize that there is a legitimate place for cannabis in medicine when it's held to the same standards as any other prescription drug," said Duane Boise, President & CEO of MMJ BioPharma Cultivation. "Our work is about delivering safe, consistent, FDA approved medicine to patients in need-not about recreational sales. The science is ready. The patients are waiting. All we need is the DEA to follow the law and issue our registration."
The Next Few Weeks Are Critical
With President Trump's announcement that a reclassification decision could come "over the next few weeks," MMJ sees a historic opportunity to align federal cannabis policy with rigorous, science-based medical development.
"If Administrator Cole acts now, the DEA can lead-not obstruct-America's transition to regulated, pharmaceutical-grade cannabis for legitimate medical use," said Boise. "This is the moment to prove that science, safety, and public health come first."
About MMJ BioPharma Cultivation
MMJ BioPharma Cultivation, a subsidiary of MMJ International Holdings, is developing proprietary, plant-derived cannabis pharmaceutical products for the treatment of Huntington's disease and Multiple Sclerosis. The company has received FDA Orphan Drug Designations, filed multiple IND applications, and operates in full compliance with FDA and DEA regulations.
MMJ is represented by attorney Megan Sheehan.
CONTACT:
Madison Hisey
[email protected]
203-231-8583
SOURCE: MMJ International Holdings
View the original press release on ACCESS Newswire
E.Rodriguez--AT